newsfilter
← Latest News
Business Wire·

Alto Neuroscience Announces Plans to Accelerate Development of ALTO-207 in Treatment Resistant Depression Following Successful Outcome from Recent FDA Meeting

– Successful outcome from recent FDA meeting guides Alto's plan to accelerate development of ALTO-207, with capital from a $50 million private placement financing expected to enable the company to initiate a Phase 3